CCR5 and HIV-1 infection: More importantly, GPI-m36.4-modified human CD4+ cells (CEMss-CCR5) were exceptionally resistant to both CCR5- and CXCR4-tropic HIV-1 isolates and had a robust selective survival advantage over unmodified cells following HIV-1 infection.